Modified Bee Venom Peptide Keeps Anti-Inflammatory Benefits Without the Toxicity

Researchers generated hydrolyzed melittin-derived peptides and evaluated them using multiple in vitro assays: ABTS radical scavenging for antioxidant activity, MTS assay for cytotoxicity in cell cultures, qPCR and Western blot for inflammatory marker expression in RAW 264.7 macrophages, and β-hexosaminidase release assay in RBL-2H3 mast cells for allergenic activity.

Bee venom therapy has been used for centuries for inflammatory conditions, but melittin's toxicity and allergenicity have prevented it from becoming a mainstream medicine. By identifying a fragment that preserves the anti-inflammatory mechanism while eliminating the dangerous side effects, this study opens a practical path toward developing safe, standardized peptide drugs from bee venom — replacing an unpredictable traditional remedy with a precisely engineered therapeutic.

Venom-derived peptides are one of the richest sources of bioactive molecules in nature. The challenge has always been separating therapeutic effects from toxic ones. This study demonstrates a systematic approach — fragmenting a venom peptide and screening derivatives — that could be applied to countless other venom peptides, potentially unlocking a library of safer drug candidates from organisms like spiders, snakes, and scorpions.

All experiments were conducted in vitro using cell lines, not in animal models or humans. The P1 peptide's stability, pharmacokinetics, and in vivo efficacy are unknown. Only one cell type was used for each assay, so the findings may not reflect responses across different tissues. The mechanism of P1's reduced toxicity was not fully elucidated.